Search research articles
Contact Us
Filters
Showing results (391-400 of 703) with videos related to
Page
of 71
Sort By:
The Lancet. Oncology
|
June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina V Long, Reinhard Dummer, Omid Hamid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 21, 2024
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
G V Long, M S Carlino, C McNeil, et al.
Cancer Immunology, Immunotherapy : CII
|
August 22, 2023
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections
C Schmitt, E P Hoefsmit, T Fangmeier, et al.
Cancers
|
December 5, 2019
Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma
Russell J Diefenbach, Jenny H Lee, Dario Strbenac, et al.
The New England Journal of Medicine
|
September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer, Axel Hauschild, Mario Santinami, et al.
The Lancet. Oncology
|
April 18, 2025
Clinical validation of droplet digital PCR assays in detecting BRAF<sup>V600</sup>-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
Mahrukh M Syeda, Georgina V Long, James Garrett, et al.
Future Oncology (London, England)
|
January 25, 2022
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence
Alexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, et al.
Journal of Translational Medicine
|
October 26, 2023
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Domenico Mallardo, Rachel Woodford, Alexander M Menzies, et al.
British Journal of Cancer
|
May 20, 2017
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
Sagun Parakh, John J Park, Shehara Mendis, et al.
JAMA Dermatology
|
March 12, 2025
Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors
Kylie A Fletcher, Rachel S Goodman, Aleigha Lawless, et al.
Page
of 71
Search research articles
Search
Showing results (391-400 of 703) with videos related to
Sort By:
Page
of 71
The Lancet. Oncology
|
June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina V Long, Reinhard Dummer, Omid Hamid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 21, 2024
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
G V Long, M S Carlino, C McNeil, et al.
Cancer Immunology, Immunotherapy : CII
|
August 22, 2023
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections
C Schmitt, E P Hoefsmit, T Fangmeier, et al.
Cancers
|
December 5, 2019
Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma
Russell J Diefenbach, Jenny H Lee, Dario Strbenac, et al.
The New England Journal of Medicine
|
September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer, Axel Hauschild, Mario Santinami, et al.
The Lancet. Oncology
|
April 18, 2025
Clinical validation of droplet digital PCR assays in detecting BRAF<sup>V600</sup>-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
Mahrukh M Syeda, Georgina V Long, James Garrett, et al.
Future Oncology (London, England)
|
January 25, 2022
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence
Alexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, et al.
Journal of Translational Medicine
|
October 26, 2023
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Domenico Mallardo, Rachel Woodford, Alexander M Menzies, et al.
British Journal of Cancer
|
May 20, 2017
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
Sagun Parakh, John J Park, Shehara Mendis, et al.
JAMA Dermatology
|
March 12, 2025
Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors
Kylie A Fletcher, Rachel S Goodman, Aleigha Lawless, et al.
Page
of 71